Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Operating Leases data on file, last reported at $65.6 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $65.6 million, down 7.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.6 million (down 7.86% YoY), and the FY2025 annual result was $67.0 million, down 7.44% from the prior year.
• Operating Leases declined to $65.6 million in Q1 2026 per KYMR's latest filing, from $67.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $77.0 million in Q4 2023 and troughed at $12.1 million in Q4 2022.
• A 5-year average of $57.5 million and a median of $69.8 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases fell 8.15% in 2022, then soared 534.18% in 2023.
• A 5-year view of Operating Leases shows it stood at $12.1 million in 2022, then soared by 534.18% to $77.0 million in 2023, then slipped by 5.98% to $72.4 million in 2024, then slipped by 7.44% to $67.0 million in 2025, then decreased by 2.16% to $65.6 million in 2026.
• Business Quant data shows KYMR's Operating Leases at $65.6 million in Q1 2026, $67.0 million in Q4 2025, and $68.4 million in Q3 2025.